We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content

Advertisement

SpringerLink
Log in

Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ohgaki H, Kleihues P. Population based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479–89.

    CAS  PubMed  Google Scholar 

  2. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results program, 1973 to 2001. Neurosurg Focus. 2006;20(4):E1.

    Article  PubMed  Google Scholar 

  3. Murovic JA, Chang SD. Outcomes after stereotactic radiosurgery and various adjuvant treatments for recurrent glioblastoma multiforme: a current literature review and comparison of multiple factors that impact outcome. World Neurosurg. 2010;78(6):588–91.

    Article  Google Scholar 

  4. Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, et al. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys. 2013;85(3):636–42.

    Article  CAS  PubMed  Google Scholar 

  5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.

    Article  CAS  PubMed  Google Scholar 

  6. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009;64:647–55.

    Article  CAS  PubMed  Google Scholar 

  7. Emerich DF, Winn SR, Snodgrass P, LaFreniere D, Agostino M, Wiens T, et al. Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors. Pharm Res. 2000;17:776–81.

    Article  CAS  PubMed  Google Scholar 

  8. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vivo drug release and in vivo drug residence in blood properties. J Control Release. 2002;79:123–35.

    Article  CAS  PubMed  Google Scholar 

  9. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood–brain barrier by nanoparticles. J Control Release. 2012;161(2):264–73.

    Article  CAS  PubMed  Google Scholar 

  10. Kundu P, Mohanty C, Sahoo SK. Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta Biomater. 2012;8(7):2670–87.

    Article  CAS  PubMed  Google Scholar 

  11. Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A. Poly(ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine. 2013;9(4):492–503.

    CAS  PubMed  Google Scholar 

  12. Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012;33(32):8167–76.

    Article  CAS  PubMed  Google Scholar 

  13. Sarkar N, Banerjee J, Hanson AJ, Elegbede AI, Rosendahl T, Krueger AB, et al. Matrix metalloproteinase-assisted triggered release of liposomal contents. Bioconjug Chem. 2008;19(1):57–64.

    Article  CAS  PubMed  Google Scholar 

  14. Gu G, Xia H, Hu Q, Liu Z, Jiang M, Kang T, et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials. 2013;34(1):196–208.

    Article  CAS  PubMed  Google Scholar 

  15. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid antitumor bioconjugate. Bioconjug Chem. 1999;10:755–63.

    Article  CAS  PubMed  Google Scholar 

  16. Freed LE, Vunjack-Novakovic G, Biron RJ, Eagles DB, Lesnoy DC, Barlow SK, et al. Biodegradable polymer scaffolds for tissue engineering. Biotechnology. 1994;12:689–93.

    Article  CAS  PubMed  Google Scholar 

  17. Ganau M, Prisco L, Pescador D, Ganau L. Challenging new targets for CNS-HIV infection. Front Neurol. 2012;3:43.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Greish K, Thiagarajan G, Ghandehari H. In vivo methods of nanotoxicology. Methods Mol Biol. 2012;926:235–53.

    Article  CAS  PubMed  Google Scholar 

  19. Knudson CB, Knudson W. Hyaluronan binding proteins in development, tissue homeostasis, and diseases. FASEB J. 1993;7:1233–41.

    CAS  PubMed  Google Scholar 

  20. Rooney P, Kumar S, Pointing J, Wang M. The role of hyaluronan in tumor neovascularization. Int J Cancer. 1995;60:632–6.

    Article  CAS  PubMed  Google Scholar 

  21. Delpech B, Maingonnat C, Girard N, Chauzy C, Maunoury R, Olivier A, et al. Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumor stroma. Eur J Cancer. 1993;29:1012–7.

    Article  Google Scholar 

  22. Akiyama Y, Jung S, Salhia B, Lee S, Hubbard S, Taylor M, et al. Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol. 2001;53:115–27.

    Article  CAS  PubMed  Google Scholar 

  23. Knüpfer MM, Poppenborg H, Hotfilder M, Kühnel K, Wolff JE, Domula M. CD44 expression and hyaluronic acid binding of malignant glioma cells. Clin Exp Metastasis. 1999;17(1):71–6.

    Article  PubMed  Google Scholar 

  24. Junker N, Latini S, Petersen LN, Kristjansen PE. Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines. Oncol Rep. 2003;10:609–16.

    CAS  PubMed  Google Scholar 

  25. Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Cho JH, et al. Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis. J Control Release. 2012;162(1):111–8.

    Article  CAS  PubMed  Google Scholar 

  26. Gilg AG, Tye SL, Tolliver LB, Wheeler WG, Visconti RP, Duncan JD, et al. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin Cancer Res. 2008;14:1804–13.

    Article  CAS  PubMed  Google Scholar 

  27. Jeong YI, Kim ST, Jin SG, Ryu HH, Jin YH, Jung TY, et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci. 2008;97:1268–76.

    Article  CAS  PubMed  Google Scholar 

  28. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, et al. TGF-β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18(6):655–68.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to Mrs Gloria Mognon for revision of the language and editing of the manuscript in its final version.

Conflict of interest

The author does not report any financial, personal or professional conflict of interest concerning the materials and methods used in this study or the findings specified in this paper.

Author information

Authors and Affiliations

  1. Department of Biomedical Engineering, University of Cagliari, Cagliari, Italy

    M. Ganau

Authors
  1. M. Ganau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Ganau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganau, M. Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles. Clin Transl Oncol 16, 220–223 (2014). https://doi.org/10.1007/s12094-013-1114-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-013-1114-1

Keywords

Search

Navigation